Xalkori

Malignant Neoplasms, Ki-1+ Anaplastic Large Cell Lymphoma

Treatment

2 FDA approvals

1 Active Study for Xalkori

What is Xalkori

Crizotinib

The Generic name of this drug

Treatment Summary

Crizotinib is a medication used to treat non-small cell lung cancer (NSCLC). It works by blocking the receptor tyrosine kinase and is only used when testing with Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit confirms the presence of an ALK fusion gene. The FDA approved Crizotinib in 2011.

Xalkori

is the brand name

image of different drug pills on a surface

Xalkori Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Xalkori

Crizotinib

2011

2

Approved as Treatment by the FDA

Crizotinib, also known as Xalkori, is approved by the FDA for 2 uses which include Metastatic Non-Small Cell Lung Cancer and Malignant Neoplasms .

Metastatic Non-Small Cell Lung Cancer

Malignant Neoplasms

Effectiveness

How Xalkori Affects Patients

In a study with 37 people with types of cancer that did not respond to other treatments, two with non-small cell lung cancer (NSCLC) responded to crizotinib. Those with advanced ALK-positive disease who took crizotinib had a 72% chance of surviving 6 months without the cancer progressing, and a 54% chance of surviving two years. Taking crizotinib may lead to liver damage, lung inflammation, heart problems, vision problems, pregnancy risks, and gastrointestinal issues in pediatric or young adult patients with ALCL or IMT.

How Xalkori works in the body

Crizotinib is a medicine that stops cancer cells from growing. It works by targeting proteins called ALK, c-MET, ROS1, and Recepteur d'Origine Nantais (RON) which help keep cancer cells alive. In laboratory tests, crizotinib was shown to stop the phosphorylation of these proteins in cancer cells, which stops them from growing. In mice with tumors that expressed ALK or c-MET, crizotinib had an antitumor effect.

When to interrupt dosage

The proposed dose of Xalkori is contingent upon the diagnosed circumstance. The measure of dosage is contingent upon the method of administration (e.g. Oral or Capsule) featured in the table beneath.

Condition

Dosage

Administration

Malignant Neoplasms

, 200.0 mg, 250.0 mg

, Oral, Capsule, Capsule - Oral

Ki-1+ Anaplastic Large Cell Lymphoma

, 200.0 mg, 250.0 mg

, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Xalkori.

Common Xalkori Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Anagrelide.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Asenapine.

Bendamustine

Major

The serum concentration of Bendamustine can be increased when it is combined with Crizotinib.

Binimetinib

Major

The serum concentration of Binimetinib can be increased when it is combined with Crizotinib.

Carfilzomib

Major

The serum concentration of Carfilzomib can be increased when it is combined with Crizotinib.

Xalkori Toxicity & Overdose Risk

The recommended dose of crizotinib is 250 mg twice daily. In the event of an overdose, supportive measures and symptomatic treatments should be used. There is no antidote for crizotinib, and tests have shown that it can be damaging to cells and has not been tested for its ability to cause cancer. In animal tests, large doses of crizotinib caused single-cell necrosis in female rats and testicular degeneration in male rats.

image of a doctor in a lab doing drug, clinical research

Xalkori Novel Uses: Which Conditions Have a Clinical Trial Featuring Xalkori?

Presently, there are 9 active trials investigating the potential of Xalkori in providing therapeutic benefits for Malignant Neoplasms.

Condition

Clinical Trials

Trial Phases

Ki-1+ Anaplastic Large Cell Lymphoma

0 Actively Recruiting

Malignant Neoplasms

3 Actively Recruiting

Phase 1, Phase 2

Xalkori Reviews: What are patients saying about Xalkori?

5

Patient Review

10/9/2018

Xalkori for ROS1 Positive Non-Small Cell Lung Cancer

This treatment has been a life-saver for me. In the two years since I've been taking it, my CEA levels have dropped from 40 to 5.8. It's given me hope and I can't thank the team who invented it enough.

5

Patient Review

1/28/2015

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I've been on this medication for a while now, and it's helped me immensely. I did have some trouble with diarrhea when I first started taking it, but that has since gone away. I do have a slow heart rate, but it's manageable. Additionally, my vision has actually improved since starting this medication, which is an unexpected bonus.

5

Patient Review

11/12/2013

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I've been taking this medication for over a year now with few negative side effects. The only downside is that I sometimes feel nauseous when I take it on an empty stomach, but otherwise it's helped me immensely.

5

Patient Review

6/29/2012

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I've been on this medication for six months and have seen significant improvement in both my lungs. I no longer experience shortness of breath or lack energy. This has been the most effective chemotherapy I've had in more than seven years by far, and with little to no negative side effects!

5

Patient Review

5/21/2014

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I've been on this drug for ten months with no terrible side effects. My cancer is all but gone, and my lymph nodes have shrunk back to a healthy size.

4.7

Patient Review

5/17/2015

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I've been using Xalkori for 39 months to treat my stage IV lung cancer. I experienced some side effects when I first started, like vision problems and nausea/constipation, but those have since become manageable. The only issue I'm having now is with lymphedema in my legs, but that's a small price to pay for such an effective cancer treatment.

2.7

Patient Review

4/4/2012

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I have experienced some side effects, like nausea and vomiting, as well as visual disturbances. However, I am pleased that the cancer has not spread elsewhere and that the size of a lymph node on my bronchus has decreased.

2

Patient Review

4/25/2014

Xalkori for ALK Positive Non-Small Cell Lung Cancer

I believe this treatment is actually killing my mother faster than the cancer would have. The swelling has made her unable to walk and now her body is shutting down from lack of circulation.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xalkori

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Xalkori chemotherapy?

"A targeted therapy is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread.

Crizotinib is the name for the chemotherapy drug that is trade-named Xalkori. In some cases, health care professionals may use Xalkori when referring to the generic drug crizotinib. Crizotinib is a targeted therapy, which is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread."

Answered by AI

What kind of drug is Xalkori?

"Xalkori is taken as a pill and can be used to treat non-small cell lung cancer. It can be used alone or with other medications, and belongs to a class of drugs called antineoplastics, which are drugs that kill cancer cells."

Answered by AI

How effective is Xalkori?

"74% of patients responded positively to Xalkori treatment, as opposed to the 45% who responded positively to chemotherapy infusions. On average, those who underwent Xalkori treatment saw their tumors shrink for 11.3 months, while those who received chemotherapy only saw their tumors shrink for 5.3 months."

Answered by AI

What does Xalkori treat?

"Crizotinib is a targeted cancer drug that treats advanced non small cell lung cancer (NSCLC) that has changes in either the ALK or ROS1 gene."

Answered by AI

Clinical Trials for Xalkori